Liquid biopsy: paving a new avenue for cancer research
The current constraints associated with cancer diagnosis and molecular profiling, which rely on invasive tissue biopsies or clinical imaging, have spurred the emergence of the liquid biopsy field. Liquid biopsy involves the extraction of circulating tumor cells (CTCs), circulating free or circulatin...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Cell Adhesion & Migration |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19336918.2024.2395807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846157554923601920 |
|---|---|
| author | Keerthi Kurma Zahra Eslami-S Catherine Alix-Panabières Laure Cayrefourcq |
| author_facet | Keerthi Kurma Zahra Eslami-S Catherine Alix-Panabières Laure Cayrefourcq |
| author_sort | Keerthi Kurma |
| collection | DOAJ |
| description | The current constraints associated with cancer diagnosis and molecular profiling, which rely on invasive tissue biopsies or clinical imaging, have spurred the emergence of the liquid biopsy field. Liquid biopsy involves the extraction of circulating tumor cells (CTCs), circulating free or circulating tumor DNA (cfDNA or ctDNA), circulating cell-free RNA (cfRNA), extracellular vesicles (EVs), and tumor-educated platelets (TEPs) from bodily fluid samples. Subsequently, these components undergo molecular characterization to identify biomarkers that are critical for early cancer detection, prognosis, therapeutic assessment, and post-treatment monitoring. These innovative biosources exhibit characteristics analogous to those of the primary tumor from which they originate or interact. This review comprehensively explores the diverse technologies and methodologies employed for processing these biosources, along with their principal clinical applications. |
| format | Article |
| id | doaj-art-b7118325b17245c287999434d5a09777 |
| institution | Kabale University |
| issn | 1933-6918 1933-6926 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Cell Adhesion & Migration |
| spelling | doaj-art-b7118325b17245c287999434d5a097772024-11-25T08:41:14ZengTaylor & Francis GroupCell Adhesion & Migration1933-69181933-69262024-12-0118112610.1080/19336918.2024.2395807Liquid biopsy: paving a new avenue for cancer researchKeerthi Kurma0Zahra Eslami-S1Catherine Alix-Panabières2Laure Cayrefourcq3Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, FranceLaboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, FranceLaboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, FranceLaboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, FranceThe current constraints associated with cancer diagnosis and molecular profiling, which rely on invasive tissue biopsies or clinical imaging, have spurred the emergence of the liquid biopsy field. Liquid biopsy involves the extraction of circulating tumor cells (CTCs), circulating free or circulating tumor DNA (cfDNA or ctDNA), circulating cell-free RNA (cfRNA), extracellular vesicles (EVs), and tumor-educated platelets (TEPs) from bodily fluid samples. Subsequently, these components undergo molecular characterization to identify biomarkers that are critical for early cancer detection, prognosis, therapeutic assessment, and post-treatment monitoring. These innovative biosources exhibit characteristics analogous to those of the primary tumor from which they originate or interact. This review comprehensively explores the diverse technologies and methodologies employed for processing these biosources, along with their principal clinical applications.https://www.tandfonline.com/doi/10.1080/19336918.2024.2395807Liquid biopsybiomarkerscirculating tumor cellscirculating free or tumor DNAcirculating cell-free RNAextracellular vesicles |
| spellingShingle | Keerthi Kurma Zahra Eslami-S Catherine Alix-Panabières Laure Cayrefourcq Liquid biopsy: paving a new avenue for cancer research Cell Adhesion & Migration Liquid biopsy biomarkers circulating tumor cells circulating free or tumor DNA circulating cell-free RNA extracellular vesicles |
| title | Liquid biopsy: paving a new avenue for cancer research |
| title_full | Liquid biopsy: paving a new avenue for cancer research |
| title_fullStr | Liquid biopsy: paving a new avenue for cancer research |
| title_full_unstemmed | Liquid biopsy: paving a new avenue for cancer research |
| title_short | Liquid biopsy: paving a new avenue for cancer research |
| title_sort | liquid biopsy paving a new avenue for cancer research |
| topic | Liquid biopsy biomarkers circulating tumor cells circulating free or tumor DNA circulating cell-free RNA extracellular vesicles |
| url | https://www.tandfonline.com/doi/10.1080/19336918.2024.2395807 |
| work_keys_str_mv | AT keerthikurma liquidbiopsypavinganewavenueforcancerresearch AT zahraeslamis liquidbiopsypavinganewavenueforcancerresearch AT catherinealixpanabieres liquidbiopsypavinganewavenueforcancerresearch AT laurecayrefourcq liquidbiopsypavinganewavenueforcancerresearch |